SHIRAGAMI Makoto

J-GLOBAL         Last updated: Nov 20, 2018 at 11:43
 
Avatar
Name
SHIRAGAMI Makoto
E-mail
m.shiragamithu.ac.jp
Affiliation
Teikyo Heisei University
Section
Faculty of Pharmaceutical Sciences Department of Pharmaceutical Sciences
Research funding number
00339243

Profile

After completion of the master course for pharmaceutical science at the graduate school of the University of Tokyo in 1977, Dr Shiragami joined the Ministry of Health and Welfare. During his service in the ministry, he engaged in various field such as new drug review, post-marketing safety issues, drug research and development promotions, and health insurance programs. From 1984 to 1985, he was sent to the Western Pacific Regional Office of the World Health Organization and then its Headquarters as an associate expert for two years. He got a PhD (Pharmaceutical science)  from the University of Tokyo in 1999. In 2001 he left the Ministry and became a professor of the College of Pharmacy, Nihon University. He is the Chairman of the Division of Regulatory Sciences, The Pharmaceutical Society of Japan and Board Members of Japanese Association for Healthcare Balanced Scorecard Studies. His fields of Specialization are pharmacoeconomics, regulations regarding pharmaceutical affairs and system of pharmaceutical affairs.

Research Areas

 
 

Academic & Professional Experience

 
Apr 2017
 - 
Today
Professor, Faculty of Pharmaceutical Science, Teikyo Heisei University
 
Apr 2001
 - 
Mar 2017
Professor, Nihon University School of Pharmacy, Department of Pharmacy
 
Apr 1977
 - 
Mar 2001
Ministry of Health
 
Apr 1984
 - 
Mar 1986
World Heath Organization
 
Aug 1999
 - 
Mar 2001
The Organization for Pharmaceutical Safety and Research
 

Education

 
 
 - 
1975
Pharmaceutical Science, Faculty of Pharmaceutical Science, The University of Tokyo
 
 
 - 
1977
Nucleic Acid Chemistry, Graduate School, Division of Pharmaceutical Sciences, The University of Tokyo
 

Published Papers

 
The Potential Public Health Impact of Herpes Zoster Vaccination of People Aged ≥ 50 Years in Japan: Results of a Markov Model Analysis
Daisuke Watanabe,Akiko Mizukami,Katsiaryna Holl, Desmond Curran, Desirée Van Oorschot, Lijoy Varghese, Makoto Shiragami
Dermatology and THerapy   8(2) 269-284   Apr 2018   [Refereed]
Rie Nakajima,Fumika Oki,Makoto Shiragami
Japanese Journal of Drug Informatics   19(3) 25-30   Nov 2017   [Refereed]
Recommendation of Regulatory Science Education in Pharmaceutical Science
Shingo Niimi, Makoto Shiragami
YKUGAKU ZASSHI   137(4) 421-426   Apr 2017   [Refereed]
Shiragami M. Mizukami A. Leeuwenkamp O. Mrkvan T. Delgleize E. Kurono Y. Iwata S
Infect Dis Ther,   4(1)    Jun 2015   [Refereed]
Tetsuya Fukuda, Hidemi Watanabe, Saeko Ido, Makoto Shiragami
Journal of Pharmaceutical Policy and Practice   7(10)    Jul 2014   [Refereed]

Misc

 
Cost-effectiveness analysis of Synflorix and Prevenar 13 in Japan: why recent published models differ in their public health conclusions?
Makoto Shiragami, Katsiaryna Holl, Tomas Mrkvan, Hatsumi Hakoda, Yuichi Kurono and Satoshi Iwata
69(3) 67-78   Mar 2016   [Refereed]
Makoto Shiragami, Akio Mizukami, Oscar Leeuwenkamp, Tomas Mrkvan, Emmanuelle Delgleize, Yuichi Kurono, Satoshi Iwata
Infect Dis Ther   4(1)    2014   [Refereed]

Books etc

 
Collaborative InnovationDeveloping Health Support Ecosystems
Routledge   2015   ISBN:978-1-138-78999-9

Conference Activities & Talks

 
EVALUATION OF A NEWLY DEVELOPED POST-MARKETING SURVEILLANCE METHOD TO VERIFY THE EFFICACY AND SAFETY OF A SWITCH-OTC DRUG
Rie Nakajima、Makoto Shiragami
The 26th Federation of Asian Pharmaceutical Associations(FAPA)Congress   10 Nov 2013   Federation of Asian Pharmaceutical Associations(FAPA)
Healthcare Reimbursement System and Use of Pharmacoeconomics in Reimbursement Process in Japan
International Society for Pharmacoeconomics and Outcomes Research First Asia-Pacific Conference   3 Sep 2003   

Research Grants & Projects

 
Pfizer Health Research Foundation: Research Grant
Project Year: Dec 2018 - Nov 2019    Investigator(s): SHIRAGAMI Makoto
Attempt to find the threshold of incremental cost-effectiveness ratio for a new drug to accept it in national health insurance
Project Year: 2007 - 2009